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:  Pancreatic cancer is frequently diagnosed at advanced stages where potentially curative 
resection is no longer possible.  Palliative procedures can be performed; however, results on a national 
level are unknown.  This study examines pancreatic cancer patients who underwent potentially palliative 
procedures including gastric bypass, biliary bypass surgery, celiac block, biliary stent, gastrostomy or 
jejunostomy, and examines post-intervention complications and 30-day mortality. 
Methods
 
:  SEER-Medicare 1991-2005 was used to identify patients with Stage 3-4 pancreatic cancer.  
Complication rates were calculated including post-op infection, myocardial infarction, aspiration 
pneumonia, DVT/PE, pulmonary compromise, gastric bleed, acute renal failure, and reoperation.  
Kaplan-Meier survival analysis was performed.  Finally, Cox proportional hazards modeling was used to 
control for the effects of age, sex, race, stage, and resection. 
Results
 
:  Of 22,314 pancreatic cancer patients, 858 (3.9%) patients were Stage 3, and 11,149 (50.0%) 
stage 4.  Post-procedure median survival for all patients is approximately two months, with longest 
survival for biliary bypass patients (3.2mo, 95% CI(2.9-3.7), and lowest survival for jejunostomy 1.3 mo 
(1.2-1.5) and gastrostomy 1.5 mo (1.4-1.8).  Post-
procedure 30-day mortality was highest for 
gastrostomy patients at 41.5%; followed by 
jejunostomy (39.1%), celiac plexus block (30.0%), 
gastric bypass (23.8%), biliary bypass (17.8%), and 
biliary stent (21.2%).  The rate of complications 
averaged 40%, with highest rate for gastrostomy 
(47.4%) and gastric bypass (45.3%) and lowest for 
celiac plexus block (29.3%).  Stage 4 disease was an 
independent predictor of death for patients undergoing five out of six procedures. 
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Conclusion:  We found that morbidity and mortality of palliative procedures in unresectable pancreatic 
cancer is high, especially in stage 4 patients.  Further studies need to be conducted to identify patients 
who will have sufficient expected post-procedure survival to benefit from these palliative interventions. 
